Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia
<p>Abstract</p> <p>Background</p> <p>To retrospectively access the outcome and toxicity of a total skin electron beam therapy (TSEBT) in patients with cutaneous lymphoma (CL) or leukemia.</p> <p>Patients and methods</p> <p>Treatment results of 25...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-07-01
|
Series: | Radiation Oncology |
Subjects: | |
Online Access: | http://www.ro-journal.com/content/7/1/118 |
id |
doaj-b44672d95f5849318032f514bd942d7b |
---|---|
record_format |
Article |
spelling |
doaj-b44672d95f5849318032f514bd942d7b2020-11-24T21:00:19ZengBMCRadiation Oncology1748-717X2012-07-017111810.1186/1748-717X-7-118Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemiaHauswald HenrikZwicker FelixRochet NathalieUhl MatthiasHensley FrankDebus JürgenHerfarth KlausBischof Marc<p>Abstract</p> <p>Background</p> <p>To retrospectively access the outcome and toxicity of a total skin electron beam therapy (TSEBT) in patients with cutaneous lymphoma (CL) or leukemia.</p> <p>Patients and methods</p> <p>Treatment results of 25 patients (median age 63 years; 5 female, 20 male) with cutaneous manifestations of advanced and therapy-refractory CL (n = 21; T-cell lymphomas n = 18, B-cell lymphomas n = 3) stage IIB-IV or leukemia (n = 4; AML n = 2, CLL n = 1, PDC n = 1) treated between 1993 and 2010 were reviewed. All patients were symptomatic. The median total dose was 29Gy, applied in 29 fractions of median 1 Gy each.</p> <p>Results</p> <p>The median follow-up was 10 months. Palliation was achieved in 23 patients (92%). A clinical complete response was documented in 13 (52%) and a partial response in 10 patients (40%). The median time to skin progression was 5 months (range 1–18 months) and the actuarial one-year progression-free survival 35%. The median overall survival (OS) after the initiation of TSEBT was 10 months (range 1–46 months) and the actuarial one-year OS 45%. TSEBT related acute adverse events (grade 1 or 2) were observed in all patients during the treatment period. An acute grade 3 epitheliolysis developed in eight patients (32%). Long-term adverse events as a hyperpigmentation of the skin (grade 1 or 2) were documented in 19 patients (76%), and a hypohidrosis in seven patients (28%).</p> <p>Conclusion</p> <p>For palliation of symptomatic cutaneous manifestations of advanced cutaneous lymphoma or leukemia, total skin electron beam therapy is an efficient and well tolerated considerable treatment option.</p> http://www.ro-journal.com/content/7/1/118TSEBTRadiotherapyIrradiationCTCLCutaneous lymphomaLymphomaLeukemia |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hauswald Henrik Zwicker Felix Rochet Nathalie Uhl Matthias Hensley Frank Debus Jürgen Herfarth Klaus Bischof Marc |
spellingShingle |
Hauswald Henrik Zwicker Felix Rochet Nathalie Uhl Matthias Hensley Frank Debus Jürgen Herfarth Klaus Bischof Marc Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia Radiation Oncology TSEBT Radiotherapy Irradiation CTCL Cutaneous lymphoma Lymphoma Leukemia |
author_facet |
Hauswald Henrik Zwicker Felix Rochet Nathalie Uhl Matthias Hensley Frank Debus Jürgen Herfarth Klaus Bischof Marc |
author_sort |
Hauswald Henrik |
title |
Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia |
title_short |
Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia |
title_full |
Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia |
title_fullStr |
Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia |
title_full_unstemmed |
Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia |
title_sort |
total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia |
publisher |
BMC |
series |
Radiation Oncology |
issn |
1748-717X |
publishDate |
2012-07-01 |
description |
<p>Abstract</p> <p>Background</p> <p>To retrospectively access the outcome and toxicity of a total skin electron beam therapy (TSEBT) in patients with cutaneous lymphoma (CL) or leukemia.</p> <p>Patients and methods</p> <p>Treatment results of 25 patients (median age 63 years; 5 female, 20 male) with cutaneous manifestations of advanced and therapy-refractory CL (n = 21; T-cell lymphomas n = 18, B-cell lymphomas n = 3) stage IIB-IV or leukemia (n = 4; AML n = 2, CLL n = 1, PDC n = 1) treated between 1993 and 2010 were reviewed. All patients were symptomatic. The median total dose was 29Gy, applied in 29 fractions of median 1 Gy each.</p> <p>Results</p> <p>The median follow-up was 10 months. Palliation was achieved in 23 patients (92%). A clinical complete response was documented in 13 (52%) and a partial response in 10 patients (40%). The median time to skin progression was 5 months (range 1–18 months) and the actuarial one-year progression-free survival 35%. The median overall survival (OS) after the initiation of TSEBT was 10 months (range 1–46 months) and the actuarial one-year OS 45%. TSEBT related acute adverse events (grade 1 or 2) were observed in all patients during the treatment period. An acute grade 3 epitheliolysis developed in eight patients (32%). Long-term adverse events as a hyperpigmentation of the skin (grade 1 or 2) were documented in 19 patients (76%), and a hypohidrosis in seven patients (28%).</p> <p>Conclusion</p> <p>For palliation of symptomatic cutaneous manifestations of advanced cutaneous lymphoma or leukemia, total skin electron beam therapy is an efficient and well tolerated considerable treatment option.</p> |
topic |
TSEBT Radiotherapy Irradiation CTCL Cutaneous lymphoma Lymphoma Leukemia |
url |
http://www.ro-journal.com/content/7/1/118 |
work_keys_str_mv |
AT hauswaldhenrik totalskinelectronbeamtherapyaspalliativetreatmentforcutaneousmanifestationsofadvancedtherapyrefractorycutaneouslymphomaandleukemia AT zwickerfelix totalskinelectronbeamtherapyaspalliativetreatmentforcutaneousmanifestationsofadvancedtherapyrefractorycutaneouslymphomaandleukemia AT rochetnathalie totalskinelectronbeamtherapyaspalliativetreatmentforcutaneousmanifestationsofadvancedtherapyrefractorycutaneouslymphomaandleukemia AT uhlmatthias totalskinelectronbeamtherapyaspalliativetreatmentforcutaneousmanifestationsofadvancedtherapyrefractorycutaneouslymphomaandleukemia AT hensleyfrank totalskinelectronbeamtherapyaspalliativetreatmentforcutaneousmanifestationsofadvancedtherapyrefractorycutaneouslymphomaandleukemia AT debusjurgen totalskinelectronbeamtherapyaspalliativetreatmentforcutaneousmanifestationsofadvancedtherapyrefractorycutaneouslymphomaandleukemia AT herfarthklaus totalskinelectronbeamtherapyaspalliativetreatmentforcutaneousmanifestationsofadvancedtherapyrefractorycutaneouslymphomaandleukemia AT bischofmarc totalskinelectronbeamtherapyaspalliativetreatmentforcutaneousmanifestationsofadvancedtherapyrefractorycutaneouslymphomaandleukemia |
_version_ |
1716780109752434688 |